Not all fat loss is equal. Losing visceral fat — the metabolically active fat packed around internal organs — produces dramatically different health outcomes than losing subcutaneous fat under the skin. GLP-1 medications and certain research peptides appear to affect these fat depots differently, and understanding why matters for anyone evaluating their options. The scale tells you how much total mass you lost. It does not tell you what kind of mass, or where from.
Two Types of Fat — Why the Distinction Matters
Your body stores fat in fundamentally different ways depending on where it is deposited. Two depots dominate the conversation around metabolic health: visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT). They look similar under a microscope but behave very differently in the body.
Visceral Adipose Tissue (VAT)
Visceral fat surrounds your abdominal organs — the liver, pancreas, kidneys, and intestines. It sits inside the peritoneal cavity, behind the abdominal muscles. You cannot pinch it. It is not the soft fat you can grab around your waist; it is deeper.
Visceral fat is metabolically active in ways that make it dangerous at high levels:
- It releases inflammatory cytokines — signaling proteins that drive chronic low-grade inflammation throughout the body
- It is more metabolically sensitive to stress hormones like cortisol, which accelerates its accumulation under chronic stress
- It drains directly into the portal vein, sending fatty acids and inflammatory signals directly to the liver — contributing to non-alcoholic fatty liver disease
- High visceral fat burden is strongly and independently associated with insulin resistance, type 2 diabetes, cardiovascular disease, and metabolic syndrome
Subcutaneous Adipose Tissue (SAT)
Subcutaneous fat sits directly under the skin — the fat you can pinch around your abdomen, hips, thighs, and arms. It is far less metabolically dangerous than visceral fat, and some research suggests that moderate amounts of subcutaneous fat may actually be metabolically protective, particularly in the gluteal-femoral region (hips and thighs). At very high quantities it contributes to metabolic dysfunction, but the dose matters more than its mere presence.
The Ratio Matters More Than Total Weight
This is the core insight that makes body composition thinking more useful than scale weight alone. A person can have a normal BMI while carrying significant visceral fat — a pattern sometimes called "normal weight obesity" or TOFI (thin outside, fat inside). Their risk profile resembles that of someone who is obese by BMI. Conversely, someone who is classified as overweight but carries most fat subcutaneously may have very different metabolic risk than the BMI would suggest.
How GLP-1 Medications Affect Fat Composition
GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) produce weight loss through multiple mechanisms. Understanding which mechanisms affect fat distribution — not just total fat — matters for interpreting what clinical trial results mean in practice.
The Caloric Deficit Mechanism
The most straightforward mechanism: GLP-1 receptor activation in the brain reduces appetite and slows gastric emptying, which leads to reduced caloric intake. Reduced caloric intake over time produces a caloric deficit, which drives fat loss. This alone does not explain preferential visceral fat loss — any caloric deficit, through any means, tends to reduce fat from all depots. The distribution of loss matters, and this is where GLP-1's direct adipose effects come in.
Direct Visceral Fat Effects
GLP-1 receptors are not only in the brain and pancreas — they are expressed in adipose tissue itself. Receptor activation in visceral fat appears to directly suppress lipogenesis (the creation and storage of new fat) and promote lipolysis (the release of stored fat for fuel). The visceral depot appears to respond more strongly than subcutaneous fat to this direct signaling. This means GLP-1 therapy is doing something beyond simply cutting calories.
What Clinical Trials Show
MRI substudies from major GLP-1 trials have measured visceral fat directly, not just total weight. The pattern is consistent: visceral fat is reduced disproportionately relative to total weight lost. Waist circumference often decreases more than scale weight would predict if all loss were proportional. These are not small effects — in trials like STEP and SURMOUNT, reductions in visceral fat markers tracked with improvements in insulin sensitivity and other metabolic markers independent of total weight loss magnitude.
The Tirzepatide Advantage
Tirzepatide (Mounjaro, Zepbound) adds GIP receptor co-agonism on top of GLP-1 activation. GIP receptors are expressed in both visceral and subcutaneous adipose tissue. SURMOUNT-1 trial data showed significant reductions in waist circumference — the best practical proxy for visceral fat — beyond what would be expected from caloric reduction alone. The dual-mechanism approach appears to produce more favorable body composition changes than GLP-1 action alone.
The Muscle Preservation Caveat
GLP-1 medications are not exempt from the universal challenge of weight loss: losing muscle alongside fat. Research suggests that without active intervention, approximately 25–40% of weight lost during significant caloric deficit may come from lean mass. GLP-1 medications suppress appetite but do not specifically protect muscle tissue. This is not a reason to avoid GLP-1 therapy — it is a reason to understand what active intervention is needed alongside it.
Basal Metabolic Rate — The Weight Loss Paradox
Basal metabolic rate (BMR) is the number of calories your body burns at rest — the energy cost of simply existing. It accounts for roughly 60–70% of total daily energy expenditure for most people. And here is the paradox: as you lose weight, your BMR decreases. This is expected physiology, not failure. A smaller body burns fewer calories at rest. What is less expected — and what derails many weight loss efforts — is how much further BMR drops beyond what weight loss alone would predict.
Adaptive Thermogenesis — The Body's Defense Against Deficit
Adaptive thermogenesis (sometimes called "metabolic adaptation") is the phenomenon where BMR drops significantly more than the reduction in body mass would predict. It is not simply that a lighter body needs fewer calories — the body actively downregulates energy expenditure in response to caloric deficit, as though conserving fuel for an anticipated famine.
Research has quantified the magnitude: BMR can drop 100–300+ kcal per day beyond what weight loss alone predicts. The famous Minnesota Starvation Study documented this in the 1940s. The Biggest Loser follow-up study, published in 2016, showed that contestants who lost dramatic weight had persistent metabolic suppression six years later — their BMR remained significantly lower than predicted even after they regained much of the weight, and their bodies had substantially reduced levels of leptin (the satiety hormone produced by fat cells).
How GLP-1s Interact with Metabolic Rate
This is an active area of research. Some early evidence suggests that GLP-1 receptor activation has central nervous system effects that may partially attenuate metabolic adaptation — not just suppress appetite, but influence the brain's regulation of energy expenditure. The GLP-1 system modulates hypothalamic circuits that control thermogenesis, and some rodent studies show increased energy expenditure with GLP-1 receptor activation independent of food intake changes. Whether this effect is clinically meaningful in humans at therapeutic doses is not yet fully established, but it may partially explain why GLP-1 therapy produces greater weight loss than caloric restriction alone predicts.
The Glucagon Pathway — Retatrutide's Third Mechanism
Retatrutide is a triple agonist in development — GLP-1 + GIP + glucagon receptor. Glucagon directly increases energy expenditure and thermogenesis; it is one of the body's primary signals to burn stored energy. Early clinical trial data for retatrutide showed weight loss that substantially exceeded what appetite suppression alone could explain — at 48 weeks, participants in the highest dose arm lost an average of approximately 24% of body weight. The glucagon receptor activation appears to genuinely increase how many calories the body burns, not just reduce how many come in. This mechanism makes triple agonists particularly interesting for the BMR problem.
What This Means in Practice
- BMR reduction during weight loss is real and significant — do not be surprised by it or interpret it as treatment failure
- Maintaining muscle mass through resistance training is the most reliable strategy for preserving BMR, since skeletal muscle is metabolically active tissue
- Protein intake at adequate levels (roughly 1g per pound of goal body weight) supports muscle preservation and has a thermogenic effect of its own — protein has a higher "thermic effect of food" than carbohydrates or fats
- GLP-1 therapy may partially attenuate metabolic adaptation through CNS mechanisms — another potential advantage over diet-alone approaches
Research Peptides and Fat Metabolism — What the Evidence Shows
Outside of approved GLP-1 medications, several research peptides are studied for potential effects on fat metabolism. The evidence quality varies significantly across compounds — some have robust animal data and interesting mechanisms, others have limited or mixed human data. Here is an honest look at each, with appropriate hedging where the science demands it.
AOD-9604 (hGH Fragment 176–191)
AOD-9604 is a synthetic fragment of human growth hormone — specifically, amino acids 176 through 191 of the hGH sequence — modified and selected specifically for its fat-burning properties while removing the growth-promoting effects of full hGH. The logic behind its development was elegant: full hGH produces lipolysis (fat release) but also carries side effects related to growth and IGF-1 stimulation. Could you get the fat-burning part without the rest? AOD-9604 was the attempt to find out.
In animal models, AOD-9604 binds to receptors on fat cells and stimulates lipolysis, with effects appearing particularly pronounced in visceral fat depots. The mechanism does not involve the growth hormone receptor pathway — instead, it appears to work through a beta-adrenergic-like mechanism on adipose tissue.
The human clinical picture is more sobering. An Australian phase 2 clinical trial did demonstrate some weight loss with AOD-9604, but the effect was modest and did not reach the threshold required for drug approval. The compound was granted GRAS (Generally Recognized As Safe) status in the United States for use as a food ingredient, which is sometimes misrepresented as evidence of efficacy — it is not. GRAS indicates a safety assessment, not that the compound produces meaningful weight loss.
AOD-9604 is available as a research peptide. The animal data on mechanism is legitimate and interesting. The human efficacy evidence, however, is limited and did not produce results strong enough to support confident claims. Anyone evaluating it should understand that distinction.
MOTS-c
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-C) is among the more scientifically interesting peptides in this space, for an unusual reason: it is not a synthetic creation — it is a natural peptide encoded within mitochondrial DNA and produced by the body itself. Its discovery in 2015 added a new chapter to our understanding of how mitochondria communicate with the rest of the cell.
MOTS-c's primary mechanism is activation of AMPK — AMP-activated protein kinase. AMPK is sometimes called the body's "energy sensor." When cellular energy is low, AMPK activates and triggers a cascade of responses: increased glucose uptake into skeletal muscle, increased fat oxidation, improved insulin sensitivity, and reduced glucose production in the liver. These are exactly the metabolic improvements you want for fat loss and metabolic health.
In animal models, MOTS-c administration produces significant improvements: reduced fat mass, improved blood glucose control, enhanced insulin sensitivity, and increased exercise capacity. One of the more striking findings is that the effects of MOTS-c are more pronounced with aging — and this is mechanistically coherent, because MOTS-c levels naturally decline with age. Some researchers have positioned MOTS-c as part of the biology of aging-related metabolic decline.
There is also an interesting exercise connection. MOTS-c activates some of the same metabolic pathways that exercise activates — enough that it has been called a potential "exercise mimetic" in some research. Circulating MOTS-c levels increase after physical exercise in humans, suggesting it may be part of how exercise produces metabolic benefits.
Human data, however, is thin. A small human study demonstrated improved insulin sensitivity with MOTS-c, which is consistent with its mechanism. But the trial was small, and the field needs substantially more human research before efficacy claims can be made confidently. MOTS-c is scientifically fascinating and mechanistically plausible — it is not yet clinically proven for fat loss in humans.
BPC-157
Body Protective Compound 157 (BPC-157) is primarily studied for tissue repair — tendon healing, gut mucosal healing, and wound repair are its main areas of animal research. It is mentioned here because some animal data suggests it may modulate growth hormone receptor expression, which could have indirect downstream effects on fat metabolism via the GH axis. However, these metabolic effects are secondary findings and far from BPC-157's main studied applications.
BPC-157 should not be evaluated as a fat-loss peptide. Its most plausible applications are in recovery and tissue healing. Anyone using it primarily for fat metabolism is extrapolating well beyond the current evidence base.
Sermorelin, CJC-1295, and Ipamorelin (GHRH/GHRP Peptides)
These peptides work by stimulating the body's own growth hormone production rather than introducing exogenous GH. Sermorelin and CJC-1295 are analogs of growth hormone-releasing hormone (GHRH), which signals the pituitary to release GH. Ipamorelin is a growth hormone-releasing peptide (GHRP) that works through a different receptor (the ghrelin receptor) to achieve a similar end result.
The connection to fat metabolism is through GH itself. Growth hormone has well-documented effects on adipose tissue: it promotes lipolysis, preferentially in visceral fat, and is strongly muscle-sparing. In adults with GH deficiency, GH therapy produces significant visceral fat reduction alongside improvements in lean mass — this is among the most robust clinical findings in endocrinology. The central question is whether GHRH/GHRP peptides produce comparable effects in adults with normal GH levels.
The answer is probably "to some degree, but less dramatically." GH levels naturally decline with age, and using GHRH peptides to raise GH toward levels typical of younger adults has theoretical appeal. But the GH-deficiency trials used pharmacological GH doses; GHRH peptides work by stimulating natural pulsatile release, which maintains physiological GH patterns rather than achieving supraphysiological levels. This may actually be a safety advantage — physiological GH pulses are how the body evolved to use GH — but it may also mean more modest effects on fat metabolism than exogenous GH produces.
Evidence quality for GHRH/GHRP peptides in healthy adults for fat loss is moderate at best. The mechanism is well-established, animal and GH-deficient patient data are strong, and the approach is conceptually sound. Controlled trials in healthy adults specifically targeting visceral fat are limited, and effect sizes in healthy people are likely smaller than in GH-deficient patients who are starting from a more significant deficit.
Visceral Fat vs. Scale Weight — What to Track
If the goal is metabolic health improvement rather than just a number on a scale, tracking needs to reflect that. Scale weight is a lagging, noisy, and often misleading signal for the outcomes that matter most.
Blood markers are underutilized as a tracking tool. Triglycerides, fasting insulin, and markers of insulin resistance (HOMA-IR) often improve meaningfully with visceral fat reduction before scale weight has changed much. Seeing those markers move can be a more accurate and motivating signal than watching a scale that is slow to budge. C-reactive protein (hsCRP) tracks the inflammatory reduction that comes with visceral fat loss. These are worth including in any baseline and follow-up lab panel for anyone doing GLP-1 therapy seriously.
Putting It Together — What This Means in Practice
The science points to several concrete conclusions for anyone navigating this space:
GLP-1 therapy produces real visceral fat reduction
The evidence here is solid. Clinical trial data — including imaging substudies — consistently shows preferential visceral fat loss with GLP-1 therapy beyond what caloric restriction alone explains. This is likely one of the primary reasons GLP-1 therapy produces such significant metabolic improvements (insulin sensitivity, blood pressure, cardiovascular risk markers) even in the first several months, before dramatic total weight loss has occurred. The fat that is coming off first is the fat that matters most metabolically.
The scale is a poor measure of metabolic progress
Waist circumference, waist-to-height ratio, and blood metabolic markers are better signals than total weight. A DEXA scan at baseline and every 3–6 months gives a complete body composition picture that the scale simply cannot provide. If the goal is metabolic health — not just a number — the measurement tools need to match the goal.
Muscle preservation requires active intervention
GLP-1 medications do not protect muscle. Losing 25–40% of lost weight as lean mass is not a hypothetical risk — it is the expected outcome without intervention. Protein at adequate levels and resistance training are not optional add-ons; they are the difference between losing fat and losing fat plus the metabolic machinery needed to sustain the results long-term. Muscle loss reduces BMR, which sets up the weight regain dynamic.
Research peptides are at different evidence stages
AOD-9604 and MOTS-c have interesting mechanisms and animal data, but limited human evidence — AOD-9604 failed to meet clinical trial thresholds for drug approval, and MOTS-c has only small human studies. GHRH peptides (sermorelin, CJC-1295, ipamorelin) have a more established mechanism through GH's well-documented visceral fat effects, with solid data in GH-deficient patients and a plausible but less proven application in healthy adults. None of these replace GLP-1 therapy in terms of clinical evidence weight.
The most evidence-backed combination
GLP-1 therapy combined with resistance training and adequate protein intake is likely more effective for body composition than any peptide combination alone. The GLP-1 handles preferential visceral fat reduction. The protein and training handle muscle preservation and BMR protection. That combination addresses the three most important variables — fat type, muscle maintenance, and metabolic rate — simultaneously. Adjunct research peptides may add marginal benefit for specific mechanisms, but they are not substitutes for the fundamentals.